Page 9 - Solid Biosciences Inc News Today

Solid Biosciences (NASDAQ:SLDB – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, Zacks.com reports. The brokerage presently has a $1.25 target price on the stock. Zacks Investment Research‘s target price suggests a potential downside of 11.97% from the company’s current […]

Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) insider Carl Ashley Morris sold 22,665 shares of Solid Biosciences stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $1.10, for a total transaction of $24,931.50. The transaction was disclosed in a legal filing with the SEC, which […]

Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2022 earnings per share estimates for shares of Solid Biosciences in a research note issued on Tuesday, March 15th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings of ($0.17) per share for the […]

Solid Biosciences (NASDAQ:SLDB – Get Rating) released its earnings results on Monday. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03, Fidelity Earnings reports. Shares of SLDB stock opened at $1.00 on Tuesday. The company has a market cap of $109.78 million, a PE ratio of […]

<p><span>Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on </span><span class="xn-chron">Monday, December 20, 2021</span><span>.</span></p>

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior

/PRNewswire/ -- Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining...

Gainers Medley Management Inc. (NASDAQ: MDLY) rose 144.9% to $14.30 in pre-market trading after gaining 9% on Wednesday. Medley LLC recently received NYSE ...

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences update call. [Operator instructions] Please be advised that todays conference is being recorded. I would now like to hand the conference over to your speaker today, Mr. Tim Palmer, corporate communications manager at Solid Biosciences. Sir, you may begin. Corporate Communications Manager Good morning. Thank you, operator. Before we get started, I would like to remind everyone that during this conferen...

Just weeks into its life as a publicly traded company, Solid Biosciences Inc (NASDAQ: SLDB) caught the eyes of four analysts who assumed coverage Tuesday with a mix of Holds and Buys. Here is what one of the more bearish critics had to say. The Rating Goldman Sachs analyst Salveen Richter... Read More...